1. Market Research
  2. >
  3. > Therapy Market Trends
  4. > Immunotherapeutics Global Market – Forecast To 2021

Immunotherapeutics Global Market – Forecast To 2021

  • November 2015
  • -
  • IQ4I Research & Consultancy Pvt. Ltd
  • -
  • 250 pages

Immunotherapy is the treatment given to suppress or amplify the immune response of a person using immunomodulators. The amplification of immune response is called as activation immunotherapy and the suppression of the immune response is called suppression immunotherapy. The global immunotherapeutics market is divided based on the segments, application and geography. Based on the segments, the immunotherapeutics are divided into monoclonal antibodies, vaccines, checkpoint inhibitors and non specific therapies. By application, the immunotherapeutics are divided into oncology, inflammatory disease, CNS and others. There are many cancer types such as lung cancer, melanoma, head and neck cancer, leukemia, colorectal cancer (CRC), lymphoma and others.

Geographical wise North America is the largest market, followed by Europe and Asia-pacific. The APAC regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the immunotherapeutics market. Growth in the Asian market is attributed to rising incidence of target diseases, growing geriatric population and better healthcare initiatives by governments and various private organizations.

The immunotherapeutics global market is expected to grow at CAGR of 4.7% to reach $138.9 billion by 2021. The factors driving the growth of this market are increasing incidence of immunological diseases such as cancer, autoimmune diseases, high potency of immunotherapy drugs over small molecule drugs, mutual agreements among the companies for drug development to commercialization, adoption of biological therapies in disease management, increasing importance of CART therapies, market penetration of key players across emerging nations, commercialization and distribution of immunotherapy drugs. In addition to this, emerging Asia Pacific and Latin American countries engaging in immunotherapeutics development and increasing government funding are some of the opportunities that are propelling the growth of the market. However, the high cost of the drug development process with a threat of failure in the end stage and reimbursement issues are hampering the growth of the market. The threat to the immunotherapeutics market is reimbursement issue.

The global immunotherapeutics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the immunotherapeutics market are AbbVie (U.S.), Amgen (U.S.), Biogen (U.S.), Bristol-Myers Squibb (U.S.), Celgene (U.S.), Johnson & Johnson (U.S.), Merck &Co., Inc (U.S.), Novartis (Switzerland), Pfizer (U.S.) and Roche (Switzerland).

Table Of Contents

Immunotherapeutics Global Market - Forecast To 2021

1 EXECUTIVE SUMMARY 16
2 INTRODUCTION 22
2.1 KEY TAKE AWAYS 22
2.2 REPORT DESCRIPTION 22
2.3 MARKETS COVERED 24
2.4 STAKEHOLDERS 25
2.5 RESEARCH METHODOLOGY 26
2.5.1 MARKET SIZE ESTIMATION 27
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 30
2.5.3 SECONDARY SOURCES 31
2.5.4 PRIMARY SOURCES 32
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 32
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 34
2.5.7 ASSUMPTIONS 34
3 MARKET ANALYSIS 36
3.1 INTRODUCTION 36
3.2 MARKET SEGMENTATION 37
3.3 FACTORS INFLUENCING MARKET 38
3.3.1 DRIVERS AND OPPORTUNITIES 39
3.3.1.1 Increasing incidence of immunological diseases such as cancer, autoimmune and infectious diseases 39
3.3.1.2 High potency of (antibodies) over small molecule drugs 39
3.3.1.3 Mutual agreements among companies from drug development to commercialization 40
3.3.1.4 Increasing importance of cart therapies 40
3.3.1.5 Adoption of biological therapies in disease management 41
3.3.1.6 Emerging asia pacific and latin american countries engaged in the development, commercialization and distribution of immunotherapy
drugs 42
3.3.1.7 Increasing government funding 42
3.3.2 RESTRAINTS AND THREATS 43
3.3.2.1 High cost of drug development process with a threat of failure in end stage 43
3.3.2.2 Reimbursement issues 44
3.4 PORTER'S FIVE FORCE ANALYSIS 45
3.4.1 THREAT OF NEW ENTRANTS 47
3.4.2 THREAT OF SUBSTITUTES 47
3.4.3 RIVALRY AMONG EXISTING COMPETITORS 47
3.4.4 BARGAINING POWER OF SUPPLIERS 48
3.4.5 BARGAINING POWER OF BUYERS 48
3.5 REGULATORY AFFAIRS 49
3.5.1 U.S. 49
3.5.2 EUROPE 50
3.5.3 CHINA 50
3.5.4 INDIA 51
3.5.5 JAPAN 52
3.6 REIMBURSMENT SCENARIO 52
3.7 PATENT ANALYSIS 55
3.8 MARKET SHARE ANALYSIS 57
4 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY TYPE 60
4.1 INTRODUCTION 60
4.2 MONOCLONAL ANTIBODIES 63
4.2.1 NAKED MONOCLONAL ANTIBODIES 64
4.2.2 CONJUGATED MONOCLONAL ANTIBODIES 66
4.2.2.1 Radio-labeled antibodies 66
4.2.2.2 Chemo-labeled antibodies 66
4.2.3 BISPECIFIC MONOCLONAL ANTIBODIES 67
4.3 THERAPEUTIC VACCINES 68
4.4 CHECKPOINT INHIBITORS 72
4.5 NON-SPECIFIC IMMUNOTHERAPY 77
4.5.1 CYTOKINES 78
4.5.2 IMMUNOMODULATING DRUGS 79
5 IMMUNOTHERAPEUTICS GLOBAL MARKET, BY APPLICATION 81
5.1 INTRODUCTION 81
5.2 ONCOLOGY 83
5.2.1 LUNG CANCER 85
5.2.2 MELANOMA 86
5.2.3 HEAD AND NECK CANCER 87
5.2.4 LEUKEMIA 87
5.2.5 COLORECTAL CANCER 88
5.2.6 LYMPHOMA 89
5.2.7 OTHERS 90
5.2.7.1 Breast cancer 90
5.2.7.2 Myeloma 91
5.2.7.3 Bladder cancer 91
5.3 INFLAMMATION 92
5.4 CENTRAL NERVOUS SYSTEM 94
5.5 OTHERS 97
5.5.1 INFECTIOUS DISEASE 99
5.5.2 OPHTHALMOLOGY 99
5.5.3 BONE HEALTH 100
6 REGIONAL MARKET ANALYSIS 101
6.1 INTRODUCTION 101
6.2 NORTH AMERICA 103
6.3 EUROPE 104
6.4 ASIA PACIFIC 104
6.5 REST OF THE WORLD 105
7 COMPANY DEVELOPMENTS 106
7.1 INTRODUCTION 106
7.1.1 AGREEMENTS, COLLABORATIONS and PARTNERSHIPS AS MAJOR GROWTH STRATEGY OF PLAYERS 106
7.1.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS AND JOINT VENTURES 108
7.2 APPROVALS 129
7.3 MERGERS AND ACQUISITIONS 140
7.4 OTHER DEVELOPMENTS 146
8 MAJOR PLAYER PROFILES 150
8.1 ABBVIE, INC. 150
8.1.1 OVERVIEW 150
8.1.2 FINANCIALS 151
8.1.3 PRODUCT PORTFOLIO 152
8.1.4 KEY DEVELOPMENTS 153
8.1.5 BUSINESS STRATEGY 155
8.1.6 SWOT ANALYSIS 156
8.2 AMGEN, INC. 157
8.2.1 OVERVIEW 157
8.2.2 FINANCIALS 157
8.2.3 PRODUCT PORTFOLIO 159
8.2.4 KEY DEVELOPMENTS 161
8.2.5 BUSINESS STRATEGY 165
8.2.6 SWOT ANALYSIS 165
8.3 BIOGEN 166
8.3.1 OVERVIEW 166
8.3.2 FINANCIALS 166
8.3.3 PRODUCT PORTFOLIO 167
8.3.4 KEY DEVELOPMENTS 168
8.3.5 BUSINESS STRATEGY 170
8.3.6 SWOT ANALYSIS 171
8.4 BRISTOL-MYERS SQUIBB 172
8.4.1 OVERVIEW 172
8.4.2 FINANCIALS 173
8.4.3 PRODUCT PORTFOLIO 176
8.4.4 KEY DEVELOPMENTS 177
8.4.5 BUSINESS STRATEGY 186
8.4.6 SWOT ANALYSIS 187
8.5 CELGENE 188
8.5.1 OVERVIEW 188
8.5.2 FINANCIALS 189
8.5.3 PRODUCT PORTFOLIO 190
8.5.4 KEY DEVELOPMENTS 191
8.5.5 BUSINESS STRATEGY 193
8.5.6 SWOT ANALYSIS 194
8.6 JOHNSON and JOHNSON 195
8.6.1 OVERVIEW 195
8.6.2 FINANCIALS 196
8.6.3 PRODUCT PORTFOLIO 198
8.6.4 KEY DEVELOPMENTS 199
8.6.5 BUSINESS STRATEGY 202
8.6.6 SWOT ANALYSIS 203
8.7 MERCK and CO, INC. 204
8.7.1 OVERVIEW 204
8.7.2 FINANCIALS 205
8.7.3 PRODUCT PORTFOLIO 207
8.7.4 KEY DEVELOPMENTS 209
8.7.5 BUSINESS STRATEGY 213
8.7.6 SWOT ANALYSIS 214
8.8 NOVARTIS AG 215
8.8.1 OVERVIEW 215
8.8.2 FINANCIALS 216
8.8.3 PRODUCT PORTFOLIO 218
8.8.4 KEY DEVELOPMENTS 220
8.8.5 BUSINESS STRATEGY 223
8.8.6 SWOT ANALYSIS 224
8.9 PFIZER, INC. 225
8.9.1 OVERVIEW 225
8.9.2 FINANCIALS 226
8.9.3 PRODUCT PORTFOLIO 228
8.9.4 KEY DEVELOPMENTS 229
8.9.5 BUSINESS STRATEGY 233
8.9.6 SWOT ANALYSIS 234
8.10 ROCHE 235
8.10.1 OVERVIEW 235
8.10.2 FINANCIALS 236
8.10.3 PRODUCT PORTFOLIO 240
8.10.4 KEY DEVELOPMENTS 243
8.10.5 BUSINESS STRATEGY 248
8.10.6 SWOT ANALYSIS 249


LIST OF TABLES

TABLE 1 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 21
TABLE 2 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE,
(2013-2021) ($MN) 62
TABLE 3 MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 64
TABLE 4 THERAPEUTIC VACCINES GLOBAL MAREKT REVENUE, BY REGION,
(2013-2021) ($MN) 72
TABLE 5 CHECKPOINT INHIBITORS GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 77
TABLE 6 NON-SPECIFIC IMMUNOTHERAPY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 78
TABLE 7 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2013-2021) ($MN) 83
TABLE 8 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 84
TABLE 9 TOP SELLING DRUGS IN ONCOLOGY SEGMENT OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 85
TABLE 10 INFLAMMATION GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 93
TABLE 11 TOP SELLING DRUGS IN INFLAMMATION OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 94
TABLE 12 CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 96
TABLE 13 TOP SELLING DRUGS IN CNS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 97
TABLE 14 OTHERS GLOBAL MARKET REVENUE, BY REGION, (2013-2021) ($MN) 98
TABLE 15 TOP SELLING DRUGS IN OTHERS OF IMMUNOTHERAPEUTICS GLOBAL MARKET, (2013-2021) ($MN) 99
TABLE 16 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS and JOINT VENTURES (2014-2015) 108
TABLE 17 APPROVALS, (2014-2015) 130
TABLE 18 MERGERS AND ACQUISITIONS, (2014-2015) 141
TABLE 19 OTHER DEVELOPMENTS (2015) 146
TABLE 20 ABBVIE, INC.: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 151
TABLE 21 ABBVIE, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 151
TABLE 22 ABBVIE, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 152
TABLE 23 AMGEN, INC.: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 157
TABLE 24 AMGEN, INC.: TOTAL REVENUE, BY PRODUCT TYPE, (2012-2014) ($MN) 158
TABLE 25 AMGEN, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 159
TABLE 26 BIOGEN: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 166
TABLE 27 BIOGEN: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 167
TABLE 28 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND RandD EXPENSES,
(2012-2014) ($MN) 173
TABLE 29 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY PRODUCT,
(2012-2014) ($MN) 174
TABLE 30 BRISTOL-MYERS SQUIBB: TOTAL REVENUE, BY GEOGRAPHY,
(2012-2014) ($MN) 175
TABLE 31 CELGENE: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 189
TABLE 32 CELGENE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 189
TABLE 33 JOHNSON and JOHNSON: TOTAL REVENUE AND RandD EXPENSES,
(2012-2014) ($MN) 196
TABLE 34 JOHNSON and JOHNSON: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 197
TABLE 35 JOHNSON and JOHNSON: TOTAL REVENUE, BY GEOGRAPHY,
(2012-2014) ($MN) 198
TABLE 36 MERCK and CO., INC.: TOTAL REVENUE AND RandD EXPENSES,
(2012-2014) ($MN) 205
TABLE 37 MERCK and CO., INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 206
TABLE 38 MERCK and CO., INC.: TOTAL REVENUE, BY GEOGRAPHY,
(2012-2014) ($MN) 207
TABLE 39 NOVARTIS AG: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 216
TABLE 40 NOVARTIS AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 217
TABLE 41 NOVARTIS AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 218
TABLE 42 PFIZER, INC.: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 226
TABLE 43 PFIZER, INC.: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 227
TABLE 44 PFIZER, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 228
TABLE 45 ROCHE: TOTAL REVENUE AND RandD EXPENSES, (2012-2014) ($MN) 236
TABLE 46 ROCHE: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN) 237
TABLE 47 ROCHE: PHARMACEUTICALS REVENUE, BY APPLICATION,
(2012-2014) ($MN) 238
TABLE 48 ROCHE: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN) 239

LIST OF FIGURES

FIGURE 1 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE, BY REGION,
(2013-2021) ($MN) 20
FIGURE 2 RESEARCH METHODOLOGY: IMMUNOTHERAPEUTICS MARKET 27
FIGURE 3 IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 28
FIGURE 4 IMMUNOTHERAPEUTICS MARKET: FORECASTING MODEL 29
FIGURE 5 IMMUNOTHERAPEUTICS MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION 30
FIGURE 6 IMMUNOTHERAPEUTICS GLOBAL MARKET: MARKET SEGMENTATION 37
FIGURE 7 MARKET DYNAMICS 38
FIGURE 8 IMMUNOTHERAPEUTICS MARKET: PORTER'S ANALYSIS 46
FIGURE 9 IMMUNOTHERAPEUTICS MARKET: PATENT FILLING BY MAJOR PLAYERS, (2011-2015) 55
FIGURE 10 IMMUNOTHERAPEUTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014 57
FIGURE 11 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY TYPE,
(2014 V'S 2021) ($MN) 61
FIGURE 12 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014 V'S 2021) ($MN) 82
FIGURE 13 IMMUNOTHERAPEUTICS GLOBAL MARKET REVENUE, BY REGION,
(2013-2021) ($MN) 102
FIGURE 14 KEY GROWTH STRATEGIES, (2014-2015) 107
FIGURE 15 SWOT: ABBVIE, INC. 156
FIGURE 16 SWOT: AMGEN, INC. 165
FIGURE 17 SWOT: BIOGEN 171
FIGURE 18 SWOT: BRISTOL-MYERS SQUIBB 187
FIGURE 19 SWOT: CELGENE 194
FIGURE 20 SWOT: JOHNSON and JOHNSON 203
FIGURE 21 SWOT: MERCK and CO., INC. 214
FIGURE 22 SWOT: NOVARTIS AG 224
FIGURE 23 SWOT: PFIZER, INC. 234
FIGURE 24 SWOT: ROCHE 249

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.